http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 30 Jul 2024 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html <p> SASKATOON, Saskatchewan--(BUSINESS WIRE)-- ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a No Objection Letter (“NOL”) from Health Canada for a proof-of-concept (“POC”) trial respecting its lead drug candidate, Trichomylin® softgel capsules. </p><p> The NOL signifies Health Canada's agreement that the safety information collected thus far regarding Trichomylin® softgel capsules supports progressing into a patient population. The POC trial aims to, among other things, http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html Tue, 30 Jul 2024 07:00:00 -0400 A.17150087 O.02548881 O.49223070 ZYUS http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html <p> SASKATOON, Saskatchewan--(BUSINESS WIRE)-- ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a No Objection Letter (“NOL”) from Health Canada for a proof-of-concept (“POC”) trial respecting its lead drug candidate, Trichomylin® softgel capsules. </p><p> The NOL signifies Health Canada's agreement that the safety information collected thus far regarding Trichomylin® softgel capsules supports progressing into a patient population. The POC trial aims to, among other things, http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html Tue, 30 Jul 2024 07:00:00 -0400 A.17150087 O.02548881 O.49223070 ZYUS http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html <p> SASKATOON, Saskatchewan--(BUSINESS WIRE)-- ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a No Objection Letter (“NOL”) from Health Canada for a proof-of-concept (“POC”) trial respecting its lead drug candidate, Trichomylin® softgel capsules. </p><p> The NOL signifies Health Canada's agreement that the safety information collected thus far regarding Trichomylin® softgel capsules supports progressing into a patient population. The POC trial aims to, among other things, http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html Tue, 30 Jul 2024 07:00:00 -0400 A.17150087 O.02548881 O.49223070 ZYUS http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html <p> SASKATOON, Saskatchewan--(BUSINESS WIRE)-- ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a No Objection Letter (“NOL”) from Health Canada for a proof-of-concept (“POC”) trial respecting its lead drug candidate, Trichomylin® softgel capsules. </p><p> The NOL signifies Health Canada's agreement that the safety information collected thus far regarding Trichomylin® softgel capsules supports progressing into a patient population. The POC trial aims to, among other things, http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html Tue, 30 Jul 2024 07:00:00 -0400 A.17150087 O.02548881 O.49223070 ZYUS http://www.streetinsider.com/Business+Wire/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html <p> SASKATOON, Saskatchewan--(BUSINESS WIRE)-- ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a No Objection Letter (“NOL”) from Health Canada for a proof-of-concept (“POC”) trial respecting its lead drug candidate, Trichomylin® softgel capsules. </p><p> The NOL signifies Health Canada's agreement that the safety information collected thus far regarding Trichomylin® softgel capsules supports progressing into a patient population. The POC trial aims to, among other things, http://www.streetinsider.com/Business+Wire/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html Tue, 30 Jul 2024 07:00:00 -0400 A.17150087 O.02548881 O.49223070 ZYUS http://www.streetinsider.com/Business+Wire/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html <p> SASKATOON, Saskatchewan--(BUSINESS WIRE)-- ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a No Objection Letter (“NOL”) from Health Canada for a proof-of-concept (“POC”) trial respecting its lead drug candidate, Trichomylin® softgel capsules. </p><p> The NOL signifies Health Canada's agreement that the safety information collected thus far regarding Trichomylin® softgel capsules supports progressing into a patient population. The POC trial aims to, among other things, http://www.streetinsider.com/Business+Wire/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html Tue, 30 Jul 2024 07:00:00 -0400 A.17150087 O.02548881 O.49223070 ZYUS http://www.streetinsider.com/Business+Wire/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html <p> SASKATOON, Saskatchewan--(BUSINESS WIRE)-- ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a No Objection Letter (“NOL”) from Health Canada for a proof-of-concept (“POC”) trial respecting its lead drug candidate, Trichomylin® softgel capsules. </p><p> The NOL signifies Health Canada's agreement that the safety information collected thus far regarding Trichomylin® softgel capsules supports progressing into a patient population. The POC trial aims to, among other things, http://www.streetinsider.com/Business+Wire/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html Tue, 30 Jul 2024 07:00:00 -0400 A.17150087 O.02548881 O.49223070 ZYUS http://www.streetinsider.com/Business+Wire/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html <p> SASKATOON, Saskatchewan--(BUSINESS WIRE)-- ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a No Objection Letter (“NOL”) from Health Canada for a proof-of-concept (“POC”) trial respecting its lead drug candidate, Trichomylin® softgel capsules. </p><p> The NOL signifies Health Canada's agreement that the safety information collected thus far regarding Trichomylin® softgel capsules supports progressing into a patient population. The POC trial aims to, among other things, http://www.streetinsider.com/Business+Wire/ZYUS+Life+Sciences+Receives+No+Objection+Letter+from+Health+Canada+for+Proof-of-Concept+Trial/23520751.html Tue, 30 Jul 2024 07:00:00 -0400 A.17150087 O.02548881 O.49223070 ZYUS